Systemic therapy with cytotoxic agents provides marginal @entity157 ( @entity157 ) treatment especially for @entity1 with advanced @entity157 . @entity900 is one of the most active cytotoxic agents for @entity157 treatment. However, acquisition of @entity900 resistance is common, and one important underlying mechanism of such resistance is apoptosis-resistance. In this study, we found that @entity64079 levels were significantly decreased in @entity157 @entity1 treated with @entity900 -based chemotherapy. @entity64079 levels were also lower in @entity900 -resistant HepG2 (HepG2-R) cells than in HepG2 cells. Exogenous @entity64079 significantly overcame @entity900 resistance in HepG2-R cells, whereas @entity64079 knockdown increased the cell viability during @entity900 treatment. We further demonstrated that @entity64079 directly targeted to @entity2423 3'-UTR (3'-Untranslated Regions). Downregulation of @entity64079 resulted in upregulation of @entity2423 which is a key member of anti-apoptotic @entity588 family and increased drug resistance. We finally demonstrated that @entity64079 decreased @entity900 resistance of @entity157 cell, partly by targeting @entity2423 . These data suggest that the combination of @entity64079 and @entity900 may represent a novel approach in treatment for @entity157 , thus offering a new target for chemotherapy of @entity157 .

Downregulation of @entity64079 increases drug resistance in XXXX -treated HepG2 by dysregulating @entity2423 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64079 :: ('574031', 'Gene') :: ['MiR-363', 'miR-363'] @entity588 :: ('596', 'Gene') :: ['Bcl-2'] @entity2423 :: ('4170', 'Gene') :: ['Mcl-1'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'benefit in hepatocellular carcinoma']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
